Open Label Study for the Use of Transcranial Ultrasound Treatment of Tremor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-13

Study Completion Date

2024-08-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Phase I open label study is to evaluate longer term tolerability and potential effectiveness of transcranial ultrasound in people with tremor as a results of Parkinson's Disease or Essential Tremor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease

NCT04002596

Parkinson Disease

COMPLETED NA

Bilateral Treatment of Medication Refractory Essential Tremor

NCT04112381

Essential Tremor

ACTIVE_NOT_RECRUITING NA

Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease

NCT07118956

Parkinson Disease Apathy Non-motor Symptoms +1 more

RECRUITING NA

A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor

NCT03253991

Essential Tremor

TERMINATED NA

Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease

NCT00036205

Parkinson Disease

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed to evaluate the safety and efficacy of focused ultrasound in patients with Parkinson's Disease or Essential Tremor characterized by tremor. The safety of this protocol will be closely monitored and data will be used to determine whether any significant safety issues exist when using focused ultrasound. Adverse events will be noted whenever they occur but will be recorded at the time of the procedure and throughout routine follow-ups, which will persist weekly throughout the duration of the active study protocol. Patients deemed potentially appropriate candidates for focused ultrasound therapy will be treated with 8 sessions of transcranial ultrasound, each of which consists of 10 to 30 minutes of active administration. Clinical and safety outcome measures will be obtained throughout and after completion of the study protocol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tremor Parkinson Disease Essential Tremor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.

Group Type EXPERIMENTAL

Focused Ultrasound

Intervention Type DEVICE

The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Focused Ultrasound

The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In order for a subject to be considered for the Essential Tremor application of this study, the following criteria are required:

Subjective complaint of tremor assessed and validated by physician

Must be willing to comply with the study protocol

English Proficiency

At least 18 years of age

At most 90 years of age

In order for a subject to be considered for the Parkinson's Disease application of this study, the following criteria are required:

Diagnosis of Parkinson's Disease validated by physician

Must be willing to comply with the study protocol

English Proficiency

At least 18 years of age

At most 90 years of age

Exclusion Criteria

In order for a subject to be considered for this study, he/she may NOT have any of the following:

Subjects not English proficient

Subjects unable to give informed consent

Subjects do not meet age requirements (18-90)

Subjects who would not be able to lay down without excessive movement in a calm environment sufficiently long enough to be able to achieve sleep

Pregnancy, women who may become pregnant or are breastfeeding

Women with child-bearing potential who are not willing to use a double-barrier birth control method

Males not willing to use a double-barrier birth control method with female sex partners with child-bearing potential

Advanced terminal illness

Any active cancer or chemotherapy

Any other neoplastic illness or illness characterized by neovascularity

Macular degeneration

Subjects with scalp rash or open wounds on the scalp (for example from treatment of squamous cell cancer)

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No